Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Genuine Parts Company (GPC) vs Stryker Corporation (SYK) Price & Performance

Genuine Parts CompanyTrade
Stryker CorporationTrade

Price performance (Past 24H)

Key statistics

Genuine Parts Company vs Stryker Corporation — how do they compare? Genuine Parts Company trades at $127.27 (market cap $17.67B), while Stryker Corporation trades at $280.41 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 6× Genuine Parts Company's market cap, and Genuine Parts Company pays the higher dividend (3.32%). Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and Stryker Corporation for 20 Days on average.

GPCSYK
Market Cap
$17.67B$106.24B
Volume
1,079,4582,982,001
Sector
Consumer CyclicalHealth
52-Week High
$149.26$388.35
52-Week Low
$92.47$269.75
Typical Hold Time
75 Days20 Days
Enterprise Value
$23.76B$117.70B
Dividend Yield
3.32%1.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Genuine Parts Company

GPC trades at $125.41, down 1.55% on the day, with a bearish technical signal and mixed fundamentals. The company reported Q2 2026 EPS of $2.15, beating expectations, but net income margin remains thin at 0.13%. Analyst consensus is mixed with 43% buy ratings and a $145.75 price target. The planned Q1 2027 separation of automotive and industrial businesses represents a key catalyst, though profitability concerns persist amid declining cash flow trends.

The outlook remains cautious with near-term pressure from weak technicals and margin compression, balanced by potential upside from the corporate split. Key risks include execution of the separation, competitive pressures in auto parts distribution, and macroeconomic sensitivity. The stock offers value at current levels for investors betting on successful restructuring, but requires careful monitoring of Q3 earnings due October 20, 2026.

Stryker Corporation

Stryker Corporation (SYK) trades at $275.40, down 1.11% amid bearish technical signals and recent negative news regarding manufacturing issues. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $3.69 versus $3.49 expected, and profitability metrics remain robust with a 14.43% net income margin. Analyst consensus remains overwhelmingly bullish with a $368.11 price target representing 33% upside potential.

Despite near-term headwinds from manufacturing disclosures and legal investigations, Stryker's solid earnings track record, strong cash flow generation, and dominant medical technology position support long-term growth prospects. Key risks include ongoing legal scrutiny and competitive pressures in the medtech sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GPC

No sentiment data available yet.

SYK
1% Buy99% Sell
Avg holding period · 20 Days

Top news

Latest headlines on both assets

About Genuine Parts Company

Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.

Read more on GPC →

About Stryker Corporation

Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.

Read more on SYK →